Søgeresultater - Matthew D. Hellmann

Refine Results
  1. 1
    PD-1/PD-L1 Axis in Lung Cancer

    PD-1/PD-L1 Axis in Lung Cancer af Fernando C. Santini, Matthew D. Hellmann

    Udgivet 2018
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  2. 2
    Acquired Resistance to Immune Checkpoint Inhibitors

    Acquired Resistance to Immune Checkpoint Inhibitors af Adam J. Schoenfeld, Matthew D. Hellmann

    Udgivet 2020
    Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  3. 3
    Chemotherapy remains an essential element of personalized care for persons with lung cancers

    Chemotherapy remains an essential element of personalized care for persons with lung cancers af Matthew D. Hellmann, Bingyu Li, Jamie E. Chaft, Mark G. Kris

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  4. 4
    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer af Solange Peters, M. Reck, Egbert F. Smit, Tony Mok, Matthew D. Hellmann

    Udgivet 2019
    Få fuldtekst Få fuldtekst
    Revisão
    Føj til favoritter
    Saved in:
  5. 5
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer af Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    Udgivet 2014
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  6. 6
    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors af Jamie E. Chaft, Matthew D. Hellmann, Moises J. Velez, William D. Travis, Valerie W. Rusch

    Udgivet 2017
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  7. 7
    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers af Jia Luo, Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann

    Udgivet 2020
    Få fuldtekst
    Carta
    Føj til favoritter
    Saved in:
  8. 8
    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing af Helena A. Yu, Maria E. Arcila, Matthew D. Hellmann, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Udgivet 2014
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  9. 9
    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics

    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics af Gregory S. Phillips, Azael Freites‐Martínez, Jennifer Wu, Donald Chan, Gabriella Fabbrocini, Matthew D. Hellmann, Mario E. Lacouture

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  10. 10
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma af Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    Udgivet 2010
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  11. 11
    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images

    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images af Jue Jiang, Yu‐Chi Hu, Chia‐Ju Liu, Darragh Halpenny, Matthew D. Hellmann, Joseph O. Deasy, G Mageras, Harini Veeraraghavan

    Udgivet 2018
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  12. 12
    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas

    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas af Juliana Schilsky, Ai Ni, Linda S. Ahn, Sutirtha Datta, William D. Travis, Mark G. Kris, Jamie E. Chaft, Natasha Rekhtman, Matthew D. Hellmann

    Udgivet 2017
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  13. 13
    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types af Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Rǎzvan Cristescu, Xiao Liu, Devan V. Mehrotra, Judong Shen, Peter Shaw, Matthew D. Hellmann, Alexandra Snyder

    Udgivet 2022
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  14. 14
    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas af Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon

    Udgivet 2015
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  15. 15
    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden af Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  16. 16
    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib af Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

    Udgivet 2019
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  17. 17
    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade af Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jeff Hammerbacher

    Udgivet 2016
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  18. 18
    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC af Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David Leung

    Udgivet 2023
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  19. 19
    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers af Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely

    Udgivet 2014
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  20. 20
    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders af Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad

    Udgivet 2018
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: